17min chapter

Biotech 2050 Podcast cover image

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Biotech 2050 Podcast

CHAPTER

Genzyme's Legacy in Rare Disease Biotech

This chapter explores how Genzyme crafted a successful business model for rare diseases by prioritizing distribution and product differentiation while cultivating trust and personal relationships in patient care. It highlights the impact of unique hiring practices and leadership strategies that emphasized risk-taking and culture maintenance, particularly after Genzyme's acquisition by Sanofi. The narrative further examines the broader implications of these practices in the biotech industry, especially regarding the evolving understanding of rare conditions like obesity.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode